Instil Bio Inc. - Asset Resilience Ratio
Instil Bio Inc. (TIL) has an Asset Resilience Ratio of 34.14% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Instil Bio Inc. carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Instil Bio Inc.'s Asset Resilience Ratio has changed over time. See shareholders equity of Instil Bio Inc. for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Instil Bio Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Instil Bio Inc. market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $69.49 Million | 34.14% |
| Total Liquid Assets | $69.49 Million | 34.14% |
Asset Resilience Insights
- Very High Liquidity: Instil Bio Inc. maintains exceptional liquid asset reserves at 34.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Instil Bio Inc. Industry Peers by Asset Resilience Ratio
Compare Instil Bio Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Instil Bio Inc. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Instil Bio Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.14% | $69.49 Million | $203.52 Million | -5.51pp |
| 2024-12-31 | 39.65% | $104.51 Million | $263.57 Million | -3.70pp |
| 2023-12-31 | 43.35% | $141.16 Million | $325.63 Million | -1.70pp |
| 2022-12-31 | 45.05% | $217.20 Million | $482.13 Million | -23.23pp |
| 2021-12-31 | 68.28% | $416.51 Million | $609.98 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $319.01 Million | -- |
About Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as … Read more